FX activator may help with bleeding control in hemophilia A and B: Trials
WHY IT MATTERS
For hemophilia patients who have developed inhibitors (antibodies that block standard treatments), bemiltenase alfa offers a potential new option for on-demand bleeding control when current therapies no longer work effectively.
Researchers tested a new medicine called bemiltenase alfa that helps control bleeding in people with hemophilia A and B. These patients had developed resistance to standard treatments, making their bleeding harder to manage. Early trial results show this new medicine may help them control bleeding when it happens.
Bemiltenase alfa, an experimental factor X (FX) activator, helped with on-demand bleeding control for people with hemophilia A and B who had developed inhibitors against standard factor replacement therapies, according to results from early clinical trials. Inhibitors are antibodies that may reduce the effectiveness of hemophilia treatments, making it more difficult to prevent and control […] The post FX activator may help with bleeding control in hemophilia A and B: Trials appeared first
ASK YOUR DOCTOR
If you have hemophilia A or B with inhibitors, ask your hematologist whether bemiltenase alfa trials are enrolling patients or when this treatment might become available.